| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_689d532e7f712c780cb4cec200f16fef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bc7e50b6d53b27b64a4358ad215a561f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5bcb6add3f990bee1616023ae6ee5b42 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5254
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5256
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24134
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24161
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-01 |
| filingDate |
2004-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3d6cc8d690efc73121b684bc2558d88
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0bb0f4cd42ad041d4bd9934e76ca0ef9 |
| publicationDate |
2005-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2005042014-A1 |
| titleOfInvention |
West nile virus vaccine |
| abstract |
A vaccine composition and method of administering same is provided that utilizes an isolated nucleic acid corresponding to substantially an entire Kunjin virus which upon administration to an animal is capable of eliciting a protective immune response to another, more pathogenic flavivirus such as West Nile virus NY 99 strain. The isolated nucleic acid may further encode at least one attenuating mutation in a Kunjin virus structural and/or non-structural protein. The isolated nucleic acid may be in the form of DNA linked to a promoter in a plasmid construct for expression in vivo or may be in the form of naked RNA or RNA packaged into VLPs. The composition and method may provide protective immunization of animals such as humans, equines and avians. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7482017-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021048402-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11680084-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020208225-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020049175-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021170869-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11351240-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021048003-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10076564-B2 |
| priorityDate |
2003-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |